Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2017

Open Access 01-12-2017 | Research article

Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV

Authors: Hironari Hanaoka, Hidehiro Yamada, Tomofumi Kiyokawa, Harunobu Iida, Takeshi Suzuki, Yoshioki Yamasaki, Seido Ooka, Hiroko Nagafuchi, Takahiro Okazaki, Daisuke Ichikawa, Sayuri Shirai, Yugo Shibagaki, Junki Koike, Shoichi Ozaki

Published in: Arthritis Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

Lupus nephritis class III or IV is associated with a poor prognosis for both patient and renal survival. Recommendations for the management of lupus nephritis have recently been established, and changing therapies is recommended for patients who do not respond adequately to induction therapy. However, it remains a major challenge to determine when to switch the treatment. In this study, we identified early prognostic factors capable of predicting poor renal outcome as well as overall damage accrual in patients with lupus nephritis class III or IV.

Methods

Eighty patients with biopsy-proven lupus nephritis class III or IV were retrospectively recruited and divided into two groups: those with complete renal response (CR) or non-CR at 3 years after induction therapy. We investigated when clinical responses were obtained at each observational period from baseline to year 3. Clinical responses were divided into three groups: CR, partial renal response (PR), and non-PR. Furthermore, patients were assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) and cumulative dose of corticosteroid for 3 years.

Results

Forty-four patients with CR and thirty-six with non-CR were enrolled. The cumulative CR rate was 85.0%. PR rates of patients with CR were significantly higher than those with non-CR from week 12 (p < 0.01). We identified the achievement of PR at 12 weeks as an independent predictor (OR 3.57, p = 0.03) by multivariate analysis. We next divided all patients into two groups according to PR achievement at week 12. The cumulative CR rate of the patients who achieved PR at week 12 was significantly higher than that of those who did not (96.5% vs 69.2%, p < 0.001). Furthermore, a significantly higher SDI and cumulative dose of corticosteroid were seen in the patients who did not achieve PR at week 12 than in those who did, regardless of their CR status, at year 3.

Conclusions

Lack of PR at week 12 predicts a lower likelihood of achieving CR at 3 years and a higher SDI.
Literature
1.
2.
go back to reference Stahl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol. 2000;27:685–91.PubMed Stahl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol. 2000;27:685–91.PubMed
3.
go back to reference Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221–5.CrossRefPubMed Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221–5.CrossRefPubMed
4.
go back to reference Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. The Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. The Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral
5.
go back to reference van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendation from an international task force. Ann Rheum Dis. 2014;73:958–67.CrossRefPubMed van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendation from an international task force. Ann Rheum Dis. 2014;73:958–67.CrossRefPubMed
6.
go back to reference Rahman P, Gladman DD, Urowitz MB, Hallet D, Tam LS. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–6.CrossRefPubMed Rahman P, Gladman DD, Urowitz MB, Hallet D, Tam LS. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–6.CrossRefPubMed
7.
go back to reference Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995–1002.CrossRefPubMed Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995–1002.CrossRefPubMed
8.
go back to reference Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50:2559–68.CrossRefPubMed Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50:2559–68.CrossRefPubMed
9.
go back to reference Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46–53.CrossRefPubMedPubMedCentral Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46–53.CrossRefPubMedPubMedCentral
10.
go back to reference Korbet SM, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: the predictive value of a ≥50% reduction in proteinuria at 6 months. Nephrol Dial Transplant. 2013;28:2313–8.CrossRefPubMed Korbet SM, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: the predictive value of a ≥50% reduction in proteinuria at 6 months. Nephrol Dial Transplant. 2013;28:2313–8.CrossRefPubMed
11.
go back to reference Tamirou F, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75:526–31.CrossRefPubMed Tamirou F, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75:526–31.CrossRefPubMed
12.
go back to reference Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
13.
go back to reference Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel BD, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. J Am Soc Nephrol. 2004;15:241–50.CrossRefPubMed Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel BD, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. J Am Soc Nephrol. 2004;15:241–50.CrossRefPubMed
14.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.CrossRefPubMed
15.
go back to reference Gladman D, Ginzler E, Goldsmith CH, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.CrossRefPubMed Gladman D, Ginzler E, Goldsmith CH, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.CrossRefPubMed
16.
go back to reference Austin HA, Boumpas DT, Vaughman EM, Balow JE. Predicting renal outcome in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544–50.CrossRefPubMed Austin HA, Boumpas DT, Vaughman EM, Balow JE. Predicting renal outcome in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544–50.CrossRefPubMed
17.
go back to reference Baldwin DS, Gluck ML, Lowenstein J, Gallo GR. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med. 1977;62:12–30.CrossRefPubMed Baldwin DS, Gluck ML, Lowenstein J, Gallo GR. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med. 1977;62:12–30.CrossRefPubMed
18.
go back to reference Donadio Jr JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151–5.CrossRefPubMed Donadio Jr JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151–5.CrossRefPubMed
19.
go back to reference Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.CrossRefPubMedPubMedCentral Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.CrossRefPubMedPubMedCentral
20.
go back to reference Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–9.PubMed Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–9.PubMed
21.
go back to reference Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Likuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2:e000066.CrossRefPubMedPubMedCentral Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Likuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2:e000066.CrossRefPubMedPubMedCentral
22.
go back to reference Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56:622–30.CrossRefPubMed Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56:622–30.CrossRefPubMed
24.
go back to reference Joo YB, Won S, Choi CB, Bae SC. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. Lupus. doi:10.1177/0961203316671813 Joo YB, Won S, Choi CB, Bae SC. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. Lupus. doi:10.​1177/​0961203316671813​
25.
go back to reference Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62:1457–68.CrossRefPubMedPubMedCentral Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62:1457–68.CrossRefPubMedPubMedCentral
Metadata
Title
Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV
Authors
Hironari Hanaoka
Hidehiro Yamada
Tomofumi Kiyokawa
Harunobu Iida
Takeshi Suzuki
Yoshioki Yamasaki
Seido Ooka
Hiroko Nagafuchi
Takahiro Okazaki
Daisuke Ichikawa
Sayuri Shirai
Yugo Shibagaki
Junki Koike
Shoichi Ozaki
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-016-1202-z

Other articles of this Issue 1/2017

Arthritis Research & Therapy 1/2017 Go to the issue